Saturday 17 October 2026
Export SPRY’s income statement to Excel — free account
ARS Pharmaceuticals, Inc.
SPRY Healthcare Biotechnology
ARS Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $84.3 million, down 5.46% from fiscal 2024. In the quarter to June 2026, revenue grew 114.2%, EPS fell 37.0%, free cash flow fell 53.7% and total debt rose 138.5%, each against the same quarter a year earlier.
4.02
0.05
−1.23%
Follow SPRY
ARS Pharmaceuticals, Inc. (SPRY) P/E ratio
ARS Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 186× (January 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 132× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 11 more quarters | Free account |
Against its own ten years
Low 0.0×
High 186×
Ten-year median
0.0×
Current reading's percentile
87
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SPRY ARS Pharmaceuticals, Inc. | n/m |
| TECX Tectonic Therapeutic, Inc. compare | n/m |
| RZLT Rezolute, Inc. compare | n/m |
| PRTA Prothena Corporation plc compare | n/m |
| PRTCY PureTech Health PLC Sponsored ADR compare | n/m |
| DMAC DiaMedica Therapeutics, Inc. compare | n/m |
| CAPR Capricor Therapeutics, Inc. compare | n/m |
| ZURA Zura Bio Limited compare | n/m |
| ASMB Assembly Biosciences, Inc. compare | 19.7× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)